Research publications | Alfred Health

Arterio-VENouS Intra Subject agreement for blood gases within intensive care: The AVENSIS study

Nanjayya VB, McCracken P, Vallance S, Board J, Kelly PJ, Schneider HG, Pilcher D, Garner DJ

(2020), Journal of the Intensive Care Society, 21(1), 64-71

DOI: 10.1177/1751143719840259

Data Sets for the Reporting of Tumors of the Central Nervous System: Recommendations From The International Collaboration on Cancer Reporting

Louis DN, Wesseling P, Brandner S, Brat DJ, Ellison DW, Giangaspero F, Hattab EM, Hawkins C, Judge MJ, Kleinschmidt-DeMasters B, Komori T, McLean C, Paulus W, Perry A, Reifenberger G, Weller M, Rous B

(2020), Arch Pathol Lab Med, 144(2), 196-206

DOI: 10.5858/arpa.2018-0565-OA

Neurotrophic interactions between neurons and astrocytes following AAV1-Rheb(S16H) transduction in the hippocampus in vivo

Jeon MT, Moon GJ, Kim S, Choi M, Oh YS, Kim DW, Kim HJ, Lee KJ, Choe Y, Ha CM, Jang IS, Nakamura M, McLean C, Chung WS, Shin WH, Lee SG, Kim SR

(2020), BRIT J PHARMACOL, 177(3), 668-86

DOI: 10.1111/bph.14882

Acral lentiginous melanoma: differences in survival compared with other subtypes.

Howard MD, Xie C, Wee E, Wolfe R, McLean CA, Kelly JW, Pan Y

(2020), Brit J Dermatol, 182(4), 1056-7

DOI: 10.1111/bjd.18620

Characterising the brain metalloproteome in Down syndrome patients with concomitant Alzheimer's pathology

Malakooti N , Roberts B , Pritchard MA , Volitakis I , Kim RC , Lott IT , McLean CA , Finkelstein DI , Adlard PA

(2020), Metallomics, 12(1), 114-32

DOI: 10.1039/c9mt00196d

Regional iron distribution and soluble ferroprotein profiles in the healthy human brain

McAllum EJ, Hare DJ, Volitakis I, McLean CA, Bush AI, Finkelstein DI, Roberts BR

(2020), Prog Neurobiol, 186, 101744

DOI: 10.1016/j.pneurobio.2019.101744

The anatomic distribution of cutaneous melanoma: A detailed study of 5141 lesions

Wee E, Wolfe R, Mclean C, Kelly JW, Pan Y

(2020), Australas J Dermatol, 61(2), 125-33

DOI: 10.1111/ajd.13223

Prognostic markers in core-binding factor AML and improved survival with multiple consolidation cycles of intermediate-/high-dose cytarabine

Prabahran A, Tacey M, Fleming S, Wei A, Tate C, Marlton P, Wight J, Grigg A, Tuckfield A, Szer J, Ritchie D, Chee L

(2020), Eur J Haematol,

Severity of mucositis during allogeneic transplantation impacts post-transplant cyclosporin absorption

Tan JLC, Wong E, Bajel A, Ramanan R, Lim ABM, Ritchie DS

(2020), BONE MARROW TRANSPL, 55(9), 1857-9

DOI: 10.1038/s41409-020-0795-7

LIM domain only 2 (LMO2) expression distinguishes T-lymphoblastic leukemia/lymphoma from indolent T-lymphoblastic proliferations

Brar N, Butzmann A, Kumar J, Peerani R, Morgan EA, Grigoriadis G, Kumar B, Tatarczuch RM, Warnke RA, Ohgami RS

(2020), Histopathology, 77(6), 984-88

DOI: 10.1111/his.14176

Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells

Teh CE, Gong JN, Segal D, Tan T, Vandenberg CJ, Fedele PL, Low MSY, Grigoriadis G, Harrison SJ, Strasser A, Roberts AW, Huang DCS, Nolan GP, Gray DHD, Ko ME

(2020), Cell Death Differ, 27(7), 2217-33

DOI: 10.1038/s41418-020-0498-z

Quality audit of the guidelines for the use of RhD immunoglobulin in obstetrics: Are we getting it right?

Glazebrook B, Akers C, Bielby L, Bastin K, Von Wielligh K, Daly J

(2020), AUST NZ J OBSTET GYN, 60(4), 504-8

DOI: 10.1111/ajo.13177

Treatment practice and outcomes in FLT3-mutant acute myeloid leukemia in the pre-midostaurin era: a real-world experience from Australian tertiary hospitals

Chua CC, Grigg A, Singh J, Droogleever MP, Zhang L, Lim A, Fong CY, Ting SB, Schwarer A, Tiong IS, Wei AH

(2020), LEUKEMIA LYMPHOMA, 61(4), 848-54

DOI: 10.1080/10428194.2019.1691192

Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial

Voso MT, Larson RA, Jones D, Marcucci G, Prior T, Krauter J, Heuser M, Lavorgna S, Nomdedeu J, Geyer SM, Walker A, Wei AH, Sierra J, Sanz MA, Brandwein JM, de Witte TM, Jansen JH, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Amadori S, Cheng Y, Chen Y, Pallaud C, Du L, Piciocchi A, Ehninger G, Byrd J, Thiede C, Döhner K, Stone RM, Döhner H, Bloomfield CD, Lo-Coco F

(2020), Blood Adv, 4(19), 4945-54

DOI: 10.1182/bloodadvances.2020002904

MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia

Montesinos P, Beckermann BM, Catalani O, Esteve J, Gamel K, Konopleva MY, Martinelli G, Monnet A, Papayannidis C, Park A, Récher C, Rodríguez-Veiga R, Röllig C, Vey N, Wei AH, Yoon SS, Fenaux P

(2020), Future Oncol, 16(13), 807-15

DOI: 10.2217/fon-2020-0044

Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

Döhner K, Thiede C, Jahn N, Panina E, Gambietz A, Larson RA, Prior TW, Marcucci G, Jones D, Krauter J, Heuser M, Voso MT, Ottone T, Nomdedeu JF, Mandrekar SJ, Klisovic RB, Wei AH, Sierra J, Sanz MA, Brandwein JM, de Witte T, Jansen JH, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Gathmann I, Benner A, Pallaud C, Stone RM, Döhner H, Bloomfield CD

(2020), Blood, 135(5), 371-80

DOI: 10.1182/blood.2019002697

New directions for emerging therapies in acute myeloid leukemia: the next chapter

Daver N, Wei AH, Pollyea DA, Fathi AT, Vyas P, DiNardo CD

(2020), Blood Cancer J, 10(10), 107

DOI: 10.1038/s41408-020-00376-1

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

Zeidan AM, Boddu PC, Patnaik MM, Bewersdorf JP, Stahl M, Rampal RK, Shallis R, Steensma DP, Savona MR, Sekeres MA, Roboz GJ, DeAngelo DJ, Schuh AC, Padron E, Zeidner JF, Walter RB, Onida F, Fathi A, DeZern A, Hobbs G, Stein EM, Vyas P, Wei AH, Bowen DT, Montesinos P, Griffiths EA, Verma AK, Keyzner A, Bar-Natan M, Navada SC, Kremyanskaya M, Goldberg AD, Al-Kali A, Heaney ML, Nazha A, Salman H, Luger S, Pratz KW, Konig H, Komrokji R, Deininger M, Cirici BX, Bhatt VR, Silverman LR, Erba HP, Fenaux P, Platzbecker U, Santini V, Wang ES, Tallman MS, Stone RM, Mascarenhas J

(2020), Lancet Haematol, 7(8), e601-12

DOI: 10.1016/S2352-3026(20)30205-2

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

Wei AH, Döhner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, Ravandi F, Sayar H, Jang JH, Porkka K, Selleslag D, Sandhu I, Turgut M, Giai V, Ofran Y, Kizil Çakar M, Botelho de Sousa A, Rybka J, Frairia C, Borin L, Beltrami G, Čermák J, Ossenkoppele GJ, La Torre I, Skikne B, Kumar K, Dong Q, Beach CL, Roboz GJ; QUAZAR AML-001 Trial Investigators

(2020), NEW ENGL J MED, 383(26), 2526-37

DOI: 10.1056/NEJMoa2004444

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P

(2020), Blood, 135(24), 2137-45

DOI: 10.1182/blood.2020004856